No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Express News | Hubei Guangji Pharmaceutical: Wholly-owned subsidiary Guanghua Pharmaceutical publicly listed for capital increase and waived preemptive subscription rights.
Overview of the lifting of restrictions on trading A-shares | February 17.
According to the Zhitong Finance APP, on February 17, a total of 19 listed companies have unlocked their restricted shares, with a total market value of approximately 6.288 billion yuan. Today's specific situation of the unlocked restricted shares is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Number Luzhou Laojiao 000568 Stock-based Incentive 0.0371 million Jinling Pharmaceutical 000919 Stock-based Incentive 1.92 million Hubei Guangji Pharmaceutical 000952 Stock-based Incentive 2.5209 million JiangSu WuZhong Pharmaceutical Development 600200 Stock-based Incentive 0.9612 million China National Software & Service 600536 Stock-based Incentive 0.0572 million Shinva Medical Instrument 6005
Guangji Pharmaceutical: 2024 Annual Results Forecast
January 20 A-shares investment warning | Lionhead Technology Development: The sales revenue from the Xiaohongshu channel in 2024 is expected to be less than 0.02 million yuan; Hubei Guangji Pharmaceutical: It is anticipated to incur a pre-loss of 0.27 bil
Shareholders of Tiande Yu, Corich LP and Richred LP, plan to collectively reduce their shareholding by no more than 2.13%; Shareholders of Liuzhou Chemical Industry, the Bank of China Guangxi Branch and China Construction Finance Lease, plan to collectively reduce their shareholding by no more than 1%; Metro Land Corporation is expected to incur a loss of 0.95 billion to 1.15 billion yuan in 2024; Hubei Guangji Pharmaceutical is expected to incur a loss of 0.27 billion to -0.299 billion yuan in 2024; Long Yuan Construction Group is expected to incur a loss of 0.4 billion to 0.6 billion yuan in 2024; Fanli Digital Technology's stocks may face delisting risk warnings; Hainan Yedao's stocks may face delisting risk warnings; Lionhead Technology Development's sales revenue through Xiaohongshu channel is expected to be insufficient in 2024.
Hubei Guangji Pharmaceutical (000952.SZ): A projected loss of 0.27 billion yuan to -0.299 billion yuan for the year 2024.
On January 17, 2024, Hubei Guangji Pharmaceutical (000952.SZ) announced its performance forecast for the fiscal year 2024, expecting a Net income loss attributable to shareholders of listed companies between 0.27 billion yuan and -0.299 billion yuan, a decrease of 92.52% to 113.19% compared to the same period last year; after excluding non-recurring gains and losses, the Net income loss is estimated to be between 0.284 billion yuan and -0.313 billion yuan, a decline of 94.14% to 113.96% compared to the same period last year; the basic EPS loss is projected to be between 0.7717 yuan/share and 0.8546 yuan/share; revenue is expected to be between 0.62 billion yuan and 0.65 billion yuan, with revenue after deductions between 0.61 billion yuan and.
Guangji Pharma to Offload Subsidiary for 45 Million Yuan
